NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: GeoVax Labs' Participation in Biotech Showcase 2026 and J.P. Morgan Healthcare Conference
TL;DR
GeoVax's participation in investor conferences offers insights into potential stock catalysts from their clinical pipeline progress and partnership opportunities.
GeoVax will present clinical data, regulatory pathways, and manufacturing advancements for COVID-19, cancer, and Mpox vaccines during January 2026 investor conferences.
GeoVax's vaccine developments for high-risk populations and scalable manufacturing could improve global health outcomes and pandemic preparedness.
GeoVax is advancing a novel oncolytic therapy for head and neck cancers alongside next-generation vaccines using continuous cell-line manufacturing.
Found this article helpful?
Share it with your network and spread the knowledge!
GeoVax Labs' senior management will engage with investors and partners to highlight the company's 2025 operational achievements, clinical pipeline progress, and strategic priorities for 2026, including key clinical catalysts, regulatory milestones, and business development opportunities.
The events will occur during Biotech Showcase 2026 and the 44th Annual J.P. Morgan Healthcare Conference Week in San Francisco from January 12-15, 2026, with a specific presentation scheduled for January 13, 2026, at 2:30 pm PST at the Hilton Union Square.
David Dodd, Chairman and CEO of GeoVax Labs, Inc., will be the presenter during the scheduled presentation on January 13, 2026.
GeoVax will discuss five key programs: CM04S1 (COVID-19 vaccine for high-risk populations), Gedeptin® (solid tumor therapy), GEO-MVA (Mpox & Smallpox vaccine), Manufacturing Platform advancements, and Business Development opportunities.
The presentation will be webcast live and accessible through the provided link or the Events & Presentations section of GeoVax's website at www.geovax.com, with an archived replay available for approximately one month after the event.
GeoVax Labs is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers, with lead programs in COVID-19 vaccination for immunocompromised patients and oncolytic therapy for head and neck cancers.
The key clinical programs include GEO-CM04S1 (a next-generation COVID-19 vaccine in three Phase 2 trials) and Gedeptin® (an oncolytic solid tumor gene-directed therapy that recently completed a Phase 1/2 trial for advanced head and neck cancers).
This participation allows GeoVax to share its progress with the global investor and biotech community, engage with shareholders and potential collaborators, and highlight how multiple programs are approaching key inflection points in 2026.
GeoVax management will host one-on-one investor and partner meetings throughout the conference to discuss the company's progress across its diverse pipeline.
Curated from NewMediaWire
